An Open-Label Study of Parsaclisib in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)

Inclusion Criteria:

- Aged 18 years or older.

- Histologically confirmed, relapsed or refractory, follicular B-cell NHL (follicular
lymphoma) Grade 1, 2, and 3a.

- Ineligible for hematopoietic stem cell transplant.

- Must have been treated with at least 2 prior systemic therapies.

- Radiographically measurable lymphadenopathy or extranodal lymphoid malignancy (defined
as the presence of ≥ 1 lesion that measures > 1.5 cm in the longest dimension and ≥
1.0 cm in the longest perpendicular dimension as assessed by computed tomography or
magnetic resonance imaging.

- Must be willing to undergo an incisional, excisional, or core needle lymph node or
tissue biopsy or provide a lymph node or tissue biopsy from the most recent available
archival tissue.

- Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.

Exclusion Criteria:

- Known histological transformation from indolent NHL to diffuse large B-cell lymphoma.

- History of central nervous system lymphoma (either primary or metastatic).

- Prior treatment with idelalisib, other selective PI3Kδ inhibitors, or a pan-PI3K
inhibitor.

- Prior treatment with a Bruton's tyrosine kinase inhibitor (eg, ibrutinib).

- Allogeneic stem cell transplant within the last 6 months, or autologous stem cell
transplant within the last 3 months before the date of study treatment administration.

- Active graft-versus-host disease.

- Subjects positive for hepatitis B surface antigen or hepatitis B core antibody will be
eligible if they are negative for HBV-DNA. Subjects positive for anti-HCV antibody
will be eligible if they are negative for HCV-RNA.